ClinicalTrials.gg
CompletedNCT04839744Updated Dec 22, 2021

A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects

A Phase 1 interventional study of TG103 produced by the modified manufacturing process and TG103 produced by the original manufacturing process in Healthy Male Subjects, sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-22.

Sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This study is designed to evaluate the comparability of TG103 injection subject to changes in the manufacturing process in Chinese healthy male subjects.

Read the detailed description

This is a randomized, open-label, parallel-group, comparative study to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, safety, and immunogenicity of TG103 injection produced by two different manufacturing processes in Chinese healthy male subjects. Approximately 24 eligible subjects will be randomized in a 1:1 ratio to receive a single dose of TG103 produced by the modified manufacturing process or TG103 produced by the original manufacturing process via subcutaneous (SC) injection.

02

Conditions studied

  • Healthy Male Subjects
03

In context

Lead sponsor

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. is the lead sponsor of 26 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Male subjects between 18 and 45 years of age, inclusive;
    1. The subject is in good health as determined by medical history, physical examination and clinical laboratory parameters, such as vital signs, 12-lead , imaging examinations (such as thyroid color Doppler ultrasound, abdominal color Doppler ultrasound, chest X-ray);
    1. Weight ≥ 50kg, (BMI) between 19-26 kg / m2 (inclusive) [BMI = weight (kg) / height 2 (m2)];
    1. The subject has a blood glucose between 3.9-6.1 mmol / L (exclusive) and the \< 6.5%;
    1. From the date of signing an to at least 3 months after the administration, the subject must use reliable methods to prevent pregnancy;
    1. The subjects fully understand the content of the trial and the possible adverse reactions, have the ability to communicate with the researchers normally, willing and able to comply with all requirements defined in the protocol;
    1. Voluntarily to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

    1. Subjects who have a history of certain allergic conditions (such as asthma, urticaria), or have a history of allergy to two or more drugs or food, or may be allergic to the test drug and the related compounds;
    1. Have a history of serious diseases, such as neurological, hepatic, renal, cardiovascular, haematological, pulmonary diseases, or other significant diseases capable of significantly altering the absorption, metabolism, or elimination of the study drug, of constituting a risk when taking the study drug; or of interfering with the interpretation of data;
    1. Have undergone major surgery within 3 months before screening or have severe infection within 4 weeks before screening;
    1. With thyroid dysfunction requiring drug treatment, or not reaching clinical stability after treatment, or with other endocrine diseases that may affect blood glucose metabolism;
    1. Have a history of or current pancreatitis (history of chronic or acute pancreatitis);
    1. Have a history of or current cholecystitis;
    1. With abnormal gastric emptying (such as gastric outlet obstruction) and severe chronic gastrointestinal diseases (such as active ulcer within 6 months);
    1. Have a history (or family history) of medullary thyroid cancer (MTC), type 2 multiple endocrine neoplasia syndrome or other hereditary diseases that are thought to induce MTC;
    1. Have a history of malignant tumour, mental illness, depression, anxiety and epilepsy;
    1. Have a history of drug dependence in the past one year or have a positive urine drug screen before administration;
    1. Vaccinated within 28 days before screening or planned to be vaccinated within 1 week after receiving the study drug;
    1. Have a positive test result of surface antigen, antibody, anti- antibody or anti-Treponema pallidum specific antibody;
    1. Blood loss greater than 400 ml due to blood donation or other reasons within 3 months before screening;
    1. Have used Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 receptor agonists or any other incretin analogues three months before the planned study drug , or other drugs that are thought to affect the trial in the opinion of the researchers;
    1. Within 3 months before administration, subjects used drugs that may cause changes in blood glucose level;
    1. Have used any prescription drug, Chinese herbal medicine or over-the-counter drug within 15 days before screening that are capable of affecting the PK, PD and safety outcomes;
    1. Average alcohol intake is more than 21 units of alcohol (male) per week (1 unit ≈ 360mL beer, or 45mL spirits with 40% alcohol content, or 150mL wine) within the 3 months prior to screening, or a positive ethanol breath test at screening;
    1. Regularly consumption of caffeine is more than 600 mg per day within the 3 months prior to screening (one cup of coffee contains about 100 mg of caffeine, one cup of tea contains about 30 mg of caffeine, and one can of coke contains about 20 mg of caffeine), or those who used caffeinated products within 48 hours before administration;
    1. Smoking more than 5 cigarettes per day within 3 months prior to screening;
    1. According to the judgment of the researcher, the subjects have special dietary requirements;
    1. With dermatitis or abnormal skin conditions at or around the site of administration;
    1. Have participated in another clinical trial involving an product within 3 months prior to the planned administration of the study drug; or the last dose of the previous investigational product has been given in less than 3 months before the screening; or those who would try to participate in other clinical trials during the study period;
    1. Not suitable for this study in the researcher's opinion, such as subjects with poor compliance (long-term business trip, planned relocation, etc.).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    TG103 produced by the modified manufacturing process

    A single dose of TG103 (15mg) produced by the modified manufacturing process will be administered subcutaneously (SC) in healthy male subjects.

    Drug: TG103 produced by the modified manufacturing process

  • Active comparator
    TG103 produced by the original manufacturing process original manufacturing process

    A single dose of TG103 (15mg) produced by the original manufacturing process will be administered subcutaneously (SC) in healthy male subjects.

    Drug: TG103 produced by the original manufacturing process

Interventions

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    Time frame: Day1-5, 7,9,10, 15, and 28

  2. Area under the plasma concentration versus time curve (AUC)

    Time frame: Day1-5, 7,9,10, 15, and 28

Secondary outcomes

  1. Change from baseline in Fasting blood glucose(FPG)

    Pharmacodynamic (PD) parameters after administration of of TG103

    Time frame: Day1-5, and 7

  2. Change from baseline in 2-hour postprandial blood glucose(2hPG)

    Pharmacodynamic (PD) parameters after administration of of TG103

    Time frame: Day1-5, and 7

  3. Number of participants with treatment-emergent adverse events

    Pharmacodynamic (PD) parameters after administration of of TG103

    Time frame: Up to 28 days

  4. Concentration of Antidrug antibodies(ADA)

    ADA after administration of of TG103

    Time frame: Day1, 15, and 28

07

Study locations

1 site
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210008, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Jun 2021, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2021
First posted
Apr 9, 2021
StartActual
May 18, 2021
Primary completionActual
Jun 15, 2021
CompletionActual
Jul 2, 2021
Last update
Dec 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04839744
Responsible party
Sponsor
First posted
Apr 9, 2021
Start date
May 18, 2021
Primary completion
Jun 15, 2021
Completion
Jul 2, 2021
Last update
Dec 22, 2021

Study contacts

Juan Li
principal investigator · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TG103

Start the discussion